Scientists Develop a More Stable Form of Glucagon to Treat Severe Low Blood Sugar

Hypoglycemia—dangerously low blood sugar—is one of the most serious day-to-day challenges for people using insulin to manage Type 1 diabetes. When blood sugar drops too low too quickly, it can cause seizures, loss of consciousness, and other medical emergencies.

Glucagon is the emergency medication that raises blood sugar fast. But the current standard glucagon kits come as a powder that caregivers must mix with liquid before injecting it. In a crisis, this extra step wastes precious minutes and can be confusing for people unfamiliar with the process.

Another major problem: traditional glucagon breaks down easily in liquid form, so it cannot be stored as a ready-to-use injection. Chemists and medical engineers have worked for years to solve this stability problem.

Researchers at the intersection of chemistry and medicine have developed a novel solution. They created tiny nanoparticles made from a sugar-based polymer called trehalose that acts like a protective coat around glucagon molecules.

Using a technique called polymerization-induced self-assembly (PISA), scientists engineered these nanoparticles to form vesicles—hollow spheres—that stabilize glucagon and prevent it from breaking down or clumping together in water.

The glucagon molecules were chemically attached to these protective nanoparticles, creating what researchers call a glucagon-vesicle conjugate. When tested in the laboratory, this formulation stayed stable for 30 days at room temperature (23–24°C) and even remained intact when heated.

Stability in the lab is important, but the real question is whether the protected glucagon still works as a medicine. Researchers tested the glucagon-vesicle conjugates in male mice with insulin-induced low blood sugar.

The results were promising: the stabilized glucagon successfully reversed the low blood sugar episodes and maintained its ability to raise glucose even after 30 days of storage at room temperature.

These findings suggest that wrapping glucagon in protective nanoparticles does not damage its biological activity—a critical step toward developing a practical, real-world medication.

If this technology advances to clinical use, the benefits could be substantial. A stable, liquid glucagon formulation would eliminate the need to mix powder during an emergency, making treatment faster and less error-prone.

Beyond emergency rescue, researchers suggest this platform could enable new approaches: smaller doses for mild-to-moderate lows, or continuous low-level infusion through an insulin pump connected to an automated glucose-monitoring system.

However, this is early-stage research conducted in the laboratory. Further testing in animals and eventually in people would be needed to prove safety and effectiveness, understand the right doses, and determine how to manufacture this formulation at scale for patients.

Source: Biomacromolecules. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.